Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Trading Plan

Derek Maetzold, CEO of Castle Biosciences, sold a portion of his holdings in company stock on December 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On December 17, 2024, Derek J Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
• A total of 9,364 shares were sold in two transactions at weighted average prices of $28.333 and $28.759.
• Following the transactions, Maetzold directly owns 84,762 shares.
• Maetzold also indirectly owns shares through various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts.
• He also holds shares through DJM Grantor Retained Annuity Trusts No. 5 and No. 6.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Insider selling can sometimes be viewed negatively by investors, but sales under pre-arranged 10b5-1 plans are common and often seen as less indicative of management's view of the company's prospects.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates